Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study
Li-Anne H Douma, Ferry Lalezari, Vincent van der Noort, Jeltje F. de Vries, Kim Monkhorst, Illaa Smesseim, Paul Baas, Bodien Schilder, Marrit Vermeulen, Jacobus A. Burgers, Cornedine J. de Gooijer
Topics & Concepts
MedicineLenvatinibPembrolizumabPemetrexedInternal medicineResponse Evaluation Criteria in Solid TumorsMesotheliomaClinical endpointOncologyProgressive diseasePhases of clinical researchChemotherapySurgeryClinical trialGastroenterologyCancerImmunotherapyPathologyThyroid cancerCisplatinOccupational and environmental lung diseasesCancer Immunotherapy and BiomarkersPleural and Pulmonary Diseases